SALT LAKE CITY, June 28, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx,"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be presenting this week at the 29th International Biodetection Technologies Conference, held virtually June 28-29, 2022.
The Biodetection Technologies Conference is an internationally recognized meeting for experts in detection & identification of biological threats, which this year plans to address the key topics in detection and present the latest R&D and technological innovation in ready-to-market systems. Company CEO Dwight Egan will be providing updates and details about the Company's upcoming PCR Home testing platform in the conference's Point-of-Care Diagnostics for Global Health and Biodefense agenda.
Mr. Egan's presentation will be broadcast on June 29 at 12:30 pm ET. To learn more about the conference, including registration details, please visit biodetectiontechnologies.com/point-of-care-diagnostics. An archived version of the presentation can be accessed on the Events and Webcasts section of the Co-Diagnostics website following the conclusion of the conference.
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers.